Inhibikase Therapeutics, Inc.IKT
Price (close)
$2.10
Market cap
$277.3M
P/E
—
Revenue (TTM)
—
Net income
-$60.6M
Dividend yield
—
1-year total return
35.5%
Net margin
—
Revenue growth
—
Debt / equity
0.00x
What Inhibikase Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $698,468 | $3.1M | $123,440 | $260,501 | $0 | — |
| Net income | -$2.8M | -$14.8M | -$18.1M | -$19.0M | -$27.5M | -$48.3M |
| Free cash flow | — | -$14.3M | -$17.6M | -$18.1M | -$19.1M | -$27.8M |
More on IKT.
- Inhibikase Therapeutics, Inc. summary
- Inhibikase Therapeutics, Inc. financial statements
- Inhibikase Therapeutics, Inc. key metrics
- Inhibikase Therapeutics, Inc. health scores and style box
- Inhibikase Therapeutics, Inc. earnings
- Inhibikase Therapeutics, Inc. dividends
- Inhibikase Therapeutics, Inc. valuation
- Inhibikase Therapeutics, Inc. ownership and insiders
- Inhibikase Therapeutics, Inc. peers
Figures from Inhibikase Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.